Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
相关临床试验
8
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
7
87.5%
招募中
1
12.5%
暂无批准数据
- Onconic Therapeutics has received a U.S. patent registration decision covering a novel high-purity, high-stability crystalline form and manufacturing method for its anticancer candidate nesuparib, valid through May 2042. - The new patent extends intellectual property protection beyond the existing compound patent (expiring 2036) to the crystal structure and production process critical for regulatory approval and commercial manufacturing. - Nesuparib is a dual-target synthetic lethal agent inhibiting both tankyrase and PARP, currently in Phase 2 trials across pancreatic, ovarian, endometrial, and gastric cancers. - The company holds three FDA orphan drug designations and is targeting submission of a U.S. Phase 2 IND application by the end of the year.
- Researchers at WEHI and MSD developed a novel vaccination approach that pairs mosquito-delivered malaria parasites with antimalarial drug candidates WM382 and MK-7602, published in Science. - The strategy arrests parasites at the late liver stage, triggering a broad, multi-layered immune response involving antibodies, CD8+ T cells, and liver-resident memory T cells. - The preclinical approach protected mice from malaria for up to two years, covering two malaria seasons, using only small parasite doses. - The drug candidates are dual inhibitors of plasmepsin IX and X, with a long-acting injectable formulation now in preclinical development.
- Neuphoria Therapeutics confirmed it is in discussions with Scancell Holdings about a potential acquisition that would result in Scancell becoming a Nasdaq-listed company. - The deal comes as Neuphoria conducts a strategic review following the failure of its Phase III AFFIRM-1 trial of BNC210 in social anxiety disorder. - Scancell seeks Nasdaq access to attract specialist biotech investors as it prepares for a pivotal Phase III study of its lead cancer immunotherapy, iSCIB1+, for advanced melanoma. - Scancell reported only £8.6 million in cash as of October 2025 and indicated the reverse merger would be paired with equity and debt financing to fund the registrational study.
- AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) received FDA approval as the first TROP2-directed antibody drug conjugate for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy. - The TROPION-Breast02 Phase III trial demonstrated a significant five-month improvement in median overall survival and a 43% reduction in disease progression risk compared to chemotherapy. - This approval addresses a critical unmet need for seven out of 10 metastatic TNBC patients who are not candidates for immunotherapy, providing a new standard of care beyond traditional chemotherapy. - The drug achieved an unprecedented median overall survival of approximately two years and an objective response rate of 64% compared to 30% with chemotherapy in the pivotal trial.
- Crown Bioscience and Turbine announced a strategic partnership to advance translational oncology research by integrating AI-driven Virtual Assays with tumor organoid validation platforms. - The collaboration creates a closed-loop approach that simulates biological responses across thousands of samples and hundreds of drugs to improve predictive accuracy and reduce experimental burden. - This integrated workflow enables researchers to generate insights earlier, streamline experimental design, and make faster decisions with greater confidence in clinical translatability. - The partnership addresses a key trade-off in drug discovery between scale and translatability by combining virtual experimentation with patient-relevant organoid models.
- TheraNym Biologics, Aurobindo Pharma's subsidiary, will invest $150-175 million to construct a new greenfield mammalian drug substance manufacturing facility under an expanded CMO agreement with MSD Singapore. - The new Unit 2 facility will house 60,000 liters of mammalian cell culture bioreactor capacity with downstream purification infrastructure to produce biologic drug substances for global markets. - This expansion builds upon the existing CMO relationship initiated in May 2024, significantly strengthening Aurobindo's biologics contract manufacturing capabilities and footprint. - The strategic investment reflects growing global demand for large-scale mammalian cell culture capacity and reinforces Aurobindo's long-term partnership with MSD in biologics manufacturing.
- Head and neck squamous cell carcinoma cases are projected to increase from 229,000 to 273,000 across eight major markets by 2034, with frail and elderly patients representing 44% of cases. - Three emerging therapies—JNJ-1900, Akalux, and Steboronine—offer new treatment options for patients who cannot tolerate intensive surgery, radiation, and platinum-based chemotherapy. - JNJ-1900 is positioned for broadest global impact with projected sales of $108 million by 2034, while Akalux targets $77.6 million in sales across the same timeframe. - These treatments focus on improving locoregional control while minimizing systemic toxicity that makes standard regimens intolerable for vulnerable patient populations.
- Kelun-Biotech received Hong Kong Stock Exchange approval to remove the "B" marker from its stock code, effective April 14, 2026, signifying achievement of higher operating standards. - The company has secured approvals for 4 products across 8 indications within three years of listing, with 3 products covering 5 indications included in China's National Reimbursement Drug List. - MSD is evaluating 17 global Phase III clinical trials for sacituzumab tirumotecan (sac-TMT), with multiple studies approaching data readout stages. - The company operates leading ADC and novel conjugation drug platforms, positioning it for continued innovation from best-in-class to first-in-class therapeutics.
- Jeito Capital successfully closed its second fund at $1.2 billion, marking the largest raise ever achieved by a fully independent European biopharma-focused fund. - The fund has tripled its assets under management to €1.6 billion in five years and will invest in 15-20 clinical-stage companies developing breakthrough therapies for severe diseases. - Jeito II addresses the pharmaceutical industry's patent cliff challenge, with potential $400 billion revenue decline by 2033, by backing innovative smaller biopharma companies. - The fund's proven strategy includes successful exits like EyeBio's acquisition by Merck for up to $3 billion and Hi-Bio's acquisition by Biogen for up to $1.8 billion.
- Merck has launched the MALBEC trial, a pivotal Phase 2b/3 study evaluating MK-8748 (Tiespectus), a novel bispecific antibody with dual Tie2 agonist/VEGF inhibitor mechanism for treating neovascular age-related macular degeneration. - The decision to advance to pivotal studies is based on positive results from the Phase 1/2a RIOJA trial, marking the first of a broader late-phase development program for this investigational therapy. - MK-8748 represents a differentiated approach to maintaining vascular stability in retinal diseases, potentially addressing the unmet need for patients who remain at risk of vision loss despite current available therapies. - The randomized, double-masked trial will compare two dose levels of MK-8748 against aflibercept 2mg in patients with wet AMD, with the primary endpoint measuring visual acuity changes over one year.
